How Are CSL (ASX:CSL), Cochlear (ASX:COH), and ResMed (ASX:RMD) Positioned as ASX Healthcare Leaders Rally on 5 November 2026?

Sonal Goyal

05 November 2026 06:16 PM AEDT

How Are CSL (ASX:CSL), Cochlear (ASX:COH), and ResMed (ASX:RMD) Positioned as ASX Healthcare Leaders Rally on 5 November 2026?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

• CSL (ASX:CSL) closed at A$202.40, up 2.56%, after entering an exclusive agreement for a rare kidney and liver disease treatment with Alentis Therapeutics.

• Cochlear (ASX:COH) closed at A$154.44, gaining 8.65%, following full-year results that came in at the upper end of revised guidance.

• ResMed (ASX:RMD) closed at A$34.61, rising 3.53%, continuing to benefit from sustained Demand for its sleep and respiratory care devices.

The S&P/ASX 200 (XJO) closed at 9,065.10 on 5 November 2026, up 2.61% or 230.60 points, while the S&P/ASX 200 Health Care index (XHJ) advanced 3.64%, adding 1,240.30 points to close at 35,329.10. The broad-based rally followed overnight Wall Street gains after Democrats posted a decisive victory in the U.S. midterm elections, providing a tailwind across global Equity markets. Three of Australia's largest healthcare companies — CSL Ltd (ASX:CSL), Cochlear Ltd (ASX:COH), and ResMed Inc (ASX:RMD) — all participated in the day's gains, reflecting broader investor appetite for the sector.

CSL Ltd — Rare Disease Pipeline Expansion

CSL Ltd (ASX:CSL), a global biotechnology company specialising in plasma-derived therapies, vaccines, and iron deficiency treatments, closed at A$202.40, up 2.56% on the session. CSL remains one of the largest companies on the ASX by market capitalisation, with operations spanning more than 40 countries.

In early October 2026, CSL announced it had entered into an exclusive agreement with Alentis Therapeutics to co-develop and co-promote lixudebart, a potential first-in-class treatment for patients with rare kidney and liver diseases. The agreement adds a new pipeline asset to CSL's portfolio and reflects the company's ongoing strategy to expand beyond its traditional plasma-derived product base. Separately, CSL disclosed on 22 October 2026 that it had been notified of a class action filed in the Supreme Court of Victoria, which the company has stated it intends to defend.

Cochlear Ltd — FY26 Results at the Upper End

Cochlear Ltd (ASX:COH), the global leader in implantable hearing solutions, closed at A$154.44 on 5 November, gaining 8.65%. The company reported its FY26 financial results on 18 August 2026 for the year ended June 2026, with Earnings coming in at the upper end of revised guidance. Cochlear has continued its strategic progress in expanding its portfolio of cochlear implants, sound processors, and bone conduction devices. The company serves patients across more than 180 countries and has maintained a track record of investing in Research and Development to support long-term growth. The FY26 result underscored continued demand for hearing solutions globally, supported by an ageing population and rising awareness of hearing loss treatment options.

ResMed Inc — Sustained Sleep and Respiratory Demand

ResMed Inc (ASX:RMD), a global leader in cloud-connected devices for the treatment of sleep apnoea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions, closed at A$34.61, rising 3.53%. ResMed operates across more than 140 countries and has increasingly integrated digital health platforms into its product offering. The company continues to benefit from favourable secular trends, including growing diagnosis rates for sleep apnoea and expanding adoption of connected care solutions. ResMed's devices and software platforms serve millions of patients globally, and the company has been investing in next-generation technologies and artificial intelligence capabilities within its digital health ecosystem.

Sector Context

The ASX healthcare sector outperformed the broader market on 5 November 2026, with the XHJ index gaining 3.64% compared to the XJO's 2.61% advance. The rally was broad-based, with large-cap names such as CSL, Cochlear, and ResMed all recording gains. The healthcare sector has historically attracted investor interest during periods of global uncertainty due to its defensive characteristics and exposure to long-term demographic trends such as ageing populations and increasing healthcare expenditure. The overnight gains on Wall Street, fuelled by the outcome of the U.S. midterm elections, provided additional momentum for Australian equities at the open.

The Road Ahead

CSL, Cochlear, and ResMed each occupy distinct positions within the ASX healthcare landscape. CSL's pipeline expansion through the Alentis agreement adds optionality to its growth trajectory, while Cochlear's FY26 results at the upper end of guidance reflect execution across its hearing solutions business. ResMed, meanwhile, continues to build on a growing addressable market for sleep and respiratory care. These three companies collectively represent a significant portion of the ASX healthcare index, and their performance on 5 November 2026 contributed meaningfully to the sector's outperformance.

FAQs

Q: What drove the ASX healthcare sector rally on 5 November 2026?

A: The S&P/ASX 200 Health Care index (XHJ) gained 3.64% on 5 November, supported by overnight Wall Street gains following the U.S. midterm election results and broad-based risk appetite across global markets.

Q: What is CSL's recent pipeline development?

A: In October 2026, CSL entered an exclusive agreement with Alentis Therapeutics to co-develop lixudebart, a potential first-in-class treatment for rare kidney and liver diseases.

Q: How did Cochlear perform in FY26?

A: Cochlear reported FY26 results at the upper end of revised guidance, reflecting continued demand for its implantable hearing solutions across more than 180 countries.

Q: What does ResMed specialise in?

A: ResMed is a global leader in cloud-connected devices and software for treating sleep apnoea, COPD, and other respiratory conditions, operating in over 140 countries.

Q: How did these three stocks perform compared to the broader market?

A: All three outperformed the S&P/ASX 200's 2.61% gain, with Cochlear up 8.65%, ResMed up 3.53%, and CSL up 2.56% at the close on 5 November 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.